Harrow Closes TYRVAYA Acquisition with Revised Terms: Japan Rights Retained by Viatris, $30M Fixed Cash Consideration
HROW is trading near its 52-week low of $28.54 (8.3% above the low).
Summary
Harrow closed its TYRVAYA acquisition from Viatris with revised terms: Viatris keeps Japan rights, cash consideration is fixed at $30M, and Harrow gains tiered royalties on Japanese sales. Management expects TYRVAYA to contribute over $30M in 2027 revenue.
Key Events · M&A and Partnerships · HROW
-
TYRVAYA Acquisition Closed
Harrow completed its acquisition of TYRVAYA (varenicline solution) nasal spray 0.03 mg from Viatris on October 1, 2026, acquiring worldwide rights except Japan.
-
Revised Deal Terms
Viatris retains Japan commercialization rights; the post-closing net working capital adjustment was eliminated, fixing cash consideration at $30.0 million, with up to $70.0 million in contingent milestone payments tied to net sales through December 31, 2029.
-
Japan Royalty Side Letter
A new side letter obligates Viatris to pay Harrow tiered royalties on annual net sales of TYRVAYA in Japan, with the parties agreeing to negotiate a collaboration agreement for Japan.
-
2027 Revenue Guidance
Harrow expects TYRVAYA to contribute more than $30 million in revenue in 2027, with commercial integration beginning in Q4 2026.
Analysis · HROW · Life Sciences
Harrow completed its acquisition of TYRVAYA from Viatris on October 1, 2026, but the deal terms changed materially from the original August announcement. Viatris now retains commercialization rights in Japan, and in exchange the post-closing working capital adjustment was eliminated, fixing the cash consideration at $30 million. A new side letter obligates Viatris to pay Harrow tiered royalties on Japanese net sales. The deal adds a second differentiated dry eye product to Harrow's ocular surface franchise, with management guiding to more than $30 million in TYRVAYA revenue in 2027 and onboarding roughly 40 experienced Viatris commercial personnel in Q4 2026.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 29.2% of the 1496 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HROW was trading at $30.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $28.54 to $54.85. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.